- Home
- PROK vs FINS Comparison
PROK vs FINS Comparison
Compare PROK & FINS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PROK
- FINS
- Stock Information
- Founded
- PROK 2015
- FINS 2019
- Country
- PROK United States
- FINS United States
- Employees
- PROK N/A
- FINS N/A
- Industry
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- FINS Finance/Investors Services
- Sector
- PROK Health Care
- FINS Finance
- Exchange
- PROK Nasdaq
- FINS Nasdaq
- Market Cap
- PROK 417.1M
- FINS 447.8M
- IPO Year
- PROK N/A
- FINS N/A
- Fundamental
- Price
- PROK $2.78
- FINS $13.27
- Analyst Decision
- PROK Strong Buy
- FINS
- Analyst Count
- PROK 4
- FINS 0
- Target Price
- PROK $6.25
- FINS N/A
- AVG Volume (30 Days)
- PROK 1.5M
- FINS 78.0K
- Earning Date
- PROK 11-10-2025
- FINS 01-01-0001
- Dividend Yield
- PROK N/A
- FINS 9.97%
- EPS Growth
- PROK N/A
- FINS N/A
- EPS
- PROK N/A
- FINS N/A
- Revenue
- PROK $744,000.00
- FINS N/A
- Revenue This Year
- PROK $471.74
- FINS N/A
- Revenue Next Year
- PROK N/A
- FINS N/A
- P/E Ratio
- PROK N/A
- FINS N/A
- Revenue Growth
- PROK N/A
- FINS N/A
- 52 Week Low
- PROK $0.46
- FINS $11.61
- 52 Week High
- PROK $7.13
- FINS $12.57
- Technical
- Relative Strength Index (RSI)
- PROK 45.61
- FINS 58.03
- Support Level
- PROK $2.56
- FINS $13.05
- Resistance Level
- PROK $2.94
- FINS $13.26
- Average True Range (ATR)
- PROK 0.23
- FINS 0.11
- MACD
- PROK -0.05
- FINS 0.02
- Stochastic Oscillator
- PROK 25.41
- FINS 91.67
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's cells isolated from the patient intended for treatment. Its product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
About FINS Angel Oak Financial Strategies Income Term Trust of Beneficial Interest
Angel Oak Financial Strats Income Term is a non-diversified, closed-end management investment company. The fund's objective is to seek current income with a secondary objective of total return. In pursuing its investment objective, the fund invests mainly in debt issued by financial institutions, including subordinated debt, unrated debt, senior debt, and high-yield securities.